

Product Information

SIGMAFAST™ Fast Red TR/Naphthol AS-MX Tablets

Tablet, to prepare 10 mL

F4523

Product Description

Fast Red TR/Naphthol AS-MX is the immunohistology substrate of choice for antibodies conjugated to alkaline phosphatase, as it produces an intense red stain. Slides stained with Fast Red TR/Naphthol AS-MX must be cover-slipped using aqueous mounting media, as the reaction product is alcohol-soluble.

SIGMAFAST™ Fast Red TR/Naphthol AS-MX Phosphate (4-Chloro-2-methylbenzenediazonium/3-Hydroxy-2-naphthoic acid 2,4-dimethylanilide phosphate) tablets have been developed for use in immunohistology and blotting, as a precipitating substrate for the detection of alkaline phosphatase activity. Levamisole has been added to a concentration of 0.15 mg/mL to block endogenous alkaline phosphatase activity.

SIGMAFAST™ Fast Red TR/Naphthol AS-MX tablets require no additional buffers or steps to prepare an active substrate solution. One Fast Red TR/Naphthol AS-MX tablet and one Trizma® buffer tablet, dissolved in 10 mL of deionized or distilled water, provides 10 mL of ready-to-use substrate. Each SIGMAFAST™ Fast Red TR/Naphthol AS-MX tablet set contains the following when dissolved in 10 mL H₂O:

- Fast Red TR: 1.0 mg/mL
- Naphthol AS-MX: 0.4 mg/mL
- Levamisole: 0.15 mg/mL
- Trizma® Buffer: 0.1 M

This product has been used to study such systems as animal models,¹⁻⁴ flatworms,⁵ cultured human cells and tissues,^{6,7} and the coeliac immune response.⁸ Other references,⁹ theses¹⁰⁻¹¹ and dissertations¹²⁻³⁰ have cited use of F4523 in their research protocols.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

Store the tablets at -20 °C.

Components

SIGMAFAST™ Fast Red TR/Naphthol AS-MX Phosphate Tablets (Component Number F0900): 5 tablets (for 5SET) or 50 tablets (for 50SET)

Trizma® Buffer Tablets (Component Number T1416): 5 tablets (for 5SET) or 50 tablets (for 50SET)

Reagents and Equipment Required but Not Provided

- Distilled or deionized water
- Pipettes
- Test tubes
- 0.2 µm filter (such as Cat. No. WHA10462701)

Preparation Instructions

1. Remove the required number of Fast Red TR/Naphthol AS-MX and Trizma® tablet packages from the freezer.
2. Allow the tablets to reach room temperature.
3. Open the Trizma® tablet package (gold foil) and drop the tablet into an appropriate container. **Do not touch the tablet with your fingers.**
4. Add 1 mL of distilled or deionized water.
5. Vortex until dissolved.
6. Open the Fast Red TR/Naphthol AS-MX tablet package (silver foil). **Do not touch the tablet with your fingers.**
7. Drop one Fast Red TR/Naphthol AS-MX tablet into the Trizma® buffer. Vortex until dissolved.

The SIGMAFAST™ Fast Red TR/Naphthol AS-MX substrate is now ready for use. For best results, the solution should be used within one hour.

Procedure

1. Cover the tissue section with 0.1-0.2 mL of Fast Red TR/Naphthol AS-MX solution.
2. Fast Red TR/Naphthol AS-MX is a fast-reacting substrate. It should be carefully monitored during the reaction to prevent overdevelopment and high background. Reactions may be stopped by gently washing the slide in water.
3. Occasionally, the Fast Red TR/Naphthol AS-MX solution may be hazy. The haziness may be removed by filtering the Fast Red TR/Naphthol AS-MX solution through a 0.2 µm filter.
4. When finished, dispose of any remaining substrate solution in a manner consistent with proper hazardous material handling protocols for your institution.

Troubleshooting

Background is too high

1. Use a blocking step prior to the application of the primary antibody. Diluted normal serum (10% v/v) from the same species as the secondary antibody generally produces the best results.
2. Decrease the staining time.
3. Titer the conjugate to optimize the working dilution.

No color develops or color is too faint

1. Adjust the concentration of the primary antibody.
2. Adjust the concentration of the secondary antibody.
3. Determine if the enzyme conjugate is active.
4. Consider using an amplifying system such as avidin-biotin.
5. Increase the staining time.
6. Determine if enzymatic treatment (unmasking) of the antigen is required prior to application of the primary antibody.

References

1. Arnold, S.J. *et al.*, *Dev. Biol.*, **296**(1), 104-118 (2006).
2. Foo, S.Y. *et al.*, *J. Immunol.*, **194**(9), 4567-4576 (2015).
3. Lokhandwala, S. *et al.*, *Clin. Vaccine Immunol.*, **23**(11), 88-900 (2016).
4. Boulenouar, S. *et al.*, *Front. Immunol.*, 10.3389 (2016).
5. Buchmann, K., *Folia Parasitol. (Praha)*, **45**(4), 312-318 (1998).
6. Noble, B. *et al.*, *Horm. Res.*, **51**(1), 31-36 (1999).
7. Ni, K. *et al.*, *Hum. Reprod.*, **31**(7), 1411-1424 (2016).
8. Comino, I. *et al.*, *Food Nutr. Res.*, **60**, 30324 (2016).
9. Moroz, L.L., and Kohn, A.B., "Analysis of Gene Expression in Neurons and Synapses by Multi-color In Situ Hybridization", in *Neuromethods*, Vol. 99: *In Situ Hybridization Methods* (Hauptmann, G., ed.). Humana Press (New York, NY), pp. 293-317 (2017).
10. Martin, Cameron Lee, "Characterization of a broadly reactive anti-CD40 agonistic monoclonal antibody for potential use as an adjuvant". Texas A&M University, M.S. thesis, p. 7 (2017).
11. Alvarez, Zita Carolina Benhadan, "Efecto del ácido fólico en la viabilidad, proliferación, morfología y diferenciación de células mesenquimales" ("Effect of folic acid on the viability, proliferation, morphology and differentiation of mesenchymal cells"). Universidad El Bosque, M.Sc. thesis, p. 39 (2020).
12. Habiba, Marwan A., "Endometrial Responses to Hormone Replacement Therapy". University of Leicester, Ph.D. dissertation, p. 262 (1998).
13. Kanczler, Janos Michael, "The Role of The Reactive Oxygen Species-Generating Enzyme, Xanthine Oxidoreductase, in Cytokine- and Hormone-Induced Bone Resorption". University of Bath, Ph.D. dissertation, p. 218 (1999).
14. Guthrie, Terry, "Characterisation of Immune Responses toward Meningococcal Antigens". University of London, Ph.D. dissertation, p. 73 (2002).
15. Jounblat, Rania Ahmad, "Complement and Surfactant Protein D in the Innate Immunity to *Streptococcus pneumoniae*". University of Leicester, Ph.D. dissertation, p. 65 (2003).
16. Lorenz, Peter Nikolai, "Latenz-assoziiertes-nukleäres-Antigen (LANA) des Humanen-Herpesvirus 8 (HHV 8) im AIDS-assoziierten Kaposi-Sarkom" ["Human herpesvirus 8 (HHV 8) latency-associated nuclear antigen (LANA) in AIDS-associated Kaposi's sarcoma"]. Ludwig-Maximilians-Universität zu München, Dr. med. dissertation, p. 136 (2007).
17. Müller, Verena, "Einfluss von Cyclooxygenase-inhibitoren auf die Anastomos-heilung nach Dickdarmresektionen im Kaninchenmodell" ("Influence of cyclooxygenase inhibitors on anastomotic healing after small bowel resection in the rabbit model"). Charité – Universitätsmedizin Berlin, Dr. med. dissertation, p. 27 (2008).

18. Thornton, Robert, "Magnesium alloys as a bioresorbable implant material". University of Manchester, Eng.D. dissertation, p. 74 (2010).
19. Ashraf, Sadaf, "Contributions of Inflammation and Angiogenesis to Structural Damage and Pain in Osteoarthritis". University of Nottingham, Ph.D. dissertation, p. 211 (2011).
20. Kanska, Justyna, "An unexpected role for Nanos in cnidarian neural stem cell fate determination". National University of Ireland Galway, Ph.D. dissertation, pp. 36 (2012).
21. Alberca, Gema Marín, "Regulación de la expresión de ciclooxigenasa-2 por calcio en macrófagos y análisis de su papel en el desarrollo de aterosclerosis" ("Regulation of cyclooxygenase-2 expression by calcium in macrophages and analysis of its role in the development of atherosclerosis"). Universidad Autónoma de Madrid, Ph.D. dissertation, p. 40 (2013).
22. Coulcher, Joshua Frederick, "Evolution of the Arthropod Mandible: a molecular developmental perspective". University College London, Ph.D. dissertation, p. 240 (2013).
23. Scherbel, Carina, "The Role of the Nuclear Receptor PPAR β/δ in the regulation of Wnt-Signaling and Bone Homeostasis". Friedrich-Alexander-Universität Erlangen-Nürnberg, Dr. rer. nat. dissertation, p. 31 (2013).
24. Depelsenaire, Alexandra C.I., "Investigation of cell death caused by the Nanopatch™ and its role in vaccine delivery as a physical immune enhancer". University of Queensland, Ph.D. dissertation, p. 98 (2014).
25. Holopainen-Mantila, Ulla, "Composition and structure of barley (*Hordeum vulgare* L.) grain in relation to end uses". University of Helsinki, Ph.D. dissertation, p. 112 (2015).
26. Dorier, Marie, "Impact du colorant alimentaire E171 et de nanoparticules de dioxyde de titane sur des modèles cellulaires, *in vitro*, d'épithélium intestinal" ("Impact of food coloring E171 and titanium dioxide nanoparticles on *in vitro* cellular models of intestinal epithelium"). Communauté Université Grenoble Alpes, Ph.D. dissertation, p. 130 (2016).
27. Fu, Travis (Sheung Ching), "Development of the chick hypothalamus". University of Sheffield, Ph.D. dissertation, p. 41 (2016).
28. Kelley, Simon P., "The role of FGFR3 in skeletal repair". University of Toronto, Ph.D. dissertation, pp. 93, 115 (2016).
29. Teng, Teng, "Molecular guidance of serotonin raphe neurons during development". Université Pierre et Marie Curie - Paris VI, Ph.D. dissertation, p. 55 (2016).
30. Lokhandwala, Shehnaz Taher, "Development of Adenovirus-Vectored Prototype Vaccines for African Swine Fever Virus and Bovine Viral Diarrhea Virus". Texas A&M University, Ph.D. dissertation, pp. 10, 11, 45, 71 (2017).
31. O'Brien, Katie Alice, "Investigation into metabolic profile changes in environmental hypoxia and the potential for dietary nitrate to alleviate hypoxic stress". King's College London, Ph.D. dissertation, p. 203 (2017).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty

The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
F4523dat Rev 03/22 PCS,RBG,GCY,MAM

MERCK